---

The Division of Non-Malignant Hematology (DNH) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products for the treatment of non-malignant hematology. 

Director: Ann Farrell

Deputy Director: Albert Deisseroth (Acting)

Deputy Director for Safety: Rosanna Setse (Acting)

Division Director of Pharm/Tox for Cardiology, Hematology, Endocrinology, and Nephrology: Todd Bourcier (Acting)

Regulatory Operations 

Chief, Project Management Staff: Charlene Wheeler (Acting)

Contact Us

Mailing Address: 

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Non-Malignant Hematology
10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4177
Phone: (301) 796-2240
Fax: (301) 796-9838

 Resources For You

• Office of Cardiology, Hematology, Endocrinology and Nephrology
• Office of New Drugs
• CDER Offices and Divisions
• Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality

---